Abstract:Mucopolysaccharidosis (MPS) IIIA, also known as Sanfilippo syndrome type A, is a severe, progressive disease that affects the central nervous system (CNS). MPS IIIA is inherited in an autosomal recessive manner and is caused by a deficiency in the lysosomal enzyme sulfamidase, which is required for the degradation of heparan sulfate. The sulfamidase is produced by the N-sulphoglucosamine sulphohydrolase (SGSH) gene. In MPS IIIA patients, the excess of lysosomal storage of heparan sulfate often leads to mental retardation, hyperactive behavior, and connective tissue impairments, which occur due to various known missense mutations in the SGSH, leading to protein dysfunction. In this study, we focused on three mutations (R74C, S66W, and R245H) based on in silico pathogenic, conservation, and stability prediction tool studies. The three mutations were further subjected to molecular dynamic simulation (MDS) analysis using GROMACS simulation software to observe the structural changes they induced, and all the mutants exhibited maximum deviation patterns compared with the native protein. Conformational changes were observed in the mutants based on various geometrical parameters, such as conformational stability, fluctuation, and compactness, followed by hydrogen bonding, physicochemical properties, principal component analysis (PCA), and salt bridge analyses, which further validated the underlying cause of the protein instability. Additionally, secondary structure and surrounding amino acid analyses further confirmed the above results indicating the loss of protein function in the mutants compared with the native protein. The present results reveal the effects of three mutations on the enzymatic activity of sulfamidase, providing a molecular explanation for the cause of the disease. Thus, this study allows for a better understanding of the effect of SGSH mutations through the use of various computational approaches in terms of both structure and functions and provides a platform for the development of therapeutic drugs and potential disease treatments.

MPS I: Early diagnosis, bone disease and treatment, where are we now?

Mucopolysaccharidosis III: Molecular basis and treatment

Molecular Mechanisms in Pathophysiology of Mucopolysaccharidosis and Prospects for Innovative Therapy

Current status and progress of mucopolysaccharidosis type Ⅰ

Mucopolysaccharidosis Type I: The Importance of Early Diagnosis for Adequate Treatment

Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond

Characterization of early markers of disease in the mouse model of mucopolysaccharidosis IIIB

The diagnosis and management of mucopolysaccharidosis type II

Mucopolysaccharidosis type VII (Sly syndrome) - What do we know?

Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment

Sanfilippo syndrome: A mini-review

Integrated management of an adult patient with Mucopolysaccharidosis type IVA: a case report with a six-year follow-up

Natural History and Clinical Assessment of Taiwanese Patients with Mucopolysaccharidosis IVA

Identification of Differential Patterns of Molecular Pathway Interactions in Bone Lesions

Delayed diagnosis of mild mucopolysaccharidosis type IVA

MPS VII - Extending the classical phenotype

Phenotypic and genetic characteristics of 130 patients with mucopolysaccharidosis type II: A single-center retrospective study in China

Bioinformatics classification of mutations in patients with Mucopolysaccharidosis IIIA

Impaired ion homeostasis as a possible associate factor in mucopolysaccharidosis pathogenesis: transcriptomic, cellular and animal studies

Otorhinolaryngological Problems in Mucopolysaccharidoses: A Review of Common Symptoms in a Rare Disease

Skeletal phenotype amelioration in mucopolysaccharidosis VI requires intervention at the earliest stages of postnatal development